Introduction
Gene transfer to hematopoietic stem cells holds significant promise for the treatment of genetic diseases, AIDS, and cancer. The use of drug resistance genes in stem cell gene therapy has two important clinical applications. First, drug selection of genetically corrected cells in vivo increases the proportion of corrected cells in gene therapy protocols for genetic diseases affecting the hematopoietic system. This strategy could circumvent the relatively low gene transfer levels obtained after non-toxic reduced-intensity conditioning regimens. Second, this strategy could also be applied to protect the bone marrow in the context of chemotherapy for solid tumors. Chemoprotection could permit dose-intensified cancer chemotherapy regimens, averting the dose-limiting myelosuppression normally associated with intensified chemotherapy regimens. [1] [2] [3] [4] Rescue with unmanipulated autologous stem cells has been widely used to this end, but this strategy allows for only a limited number of high-dose chemotherapy cycles and is still limited by short periods of significant myelosuppression in the period immediately after transplantation. In contrast, a genetically protected bone marrow could make possible tightly spaced dose-intense chemotherapy regimens over extended time periods in the complete absence of any myelosuppression.
A particularly attractive drug resistance gene for the use in gene therapy is the DNA-repair enzyme methylguanine methyltransferase (MGMT). 3, 4 Overexpression of this enzyme renders primary hematopoietic cells resistant to nitrosoureas such as carmustine (BCNU) [3] [4] [5] [6] and to methylating agents, such as temozolomide. 7 Resistance to nitrosoureas in human cancer has been linked to elevated protein-levels of endogenous MGMT. 8 To overcome this documented Importantly, survival and time to disease progression in glioma patients are favorably correlated to methylation and subsequent silencing of the endogenous MGMT promoter.
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The clinical use of O 6 BG and BCNU is limited by myelosuppression. 10 Mutants of MGMT insensitive to the inhibitory action of O 6 BG have been developed for the use in gene therapy. 12, 13 These have been shown to confer resistance to the drug combination of O 6 BG and BCNU 5, 6 or O 6 BG and temozolomide 7 in vivo in mouse models of stem cell gene therapy.
Successful in vivo selection of genetically modified hematopoietic cells has been first reported in murine models over 10 years ago using MDR-1 as a drug resistance gene. 1, 14 Later, in vivo selection in the murine model has also been reported for other selectable markers, DHFR 15 and MGMT. [4] [5] [6] [7] These murine studies have set the stage for large animal experiments and clinical trials. For both MDR-1 and DHFR, evaluation in clinically more relevant large animals essentially documented less pronounced in vivo selection with unlikely clinical benefit or excessive toxicity.
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MDR-1 has been tested in clinical trials, 
Viral vectors
The oncoretroviral vector plasmid, MIEG3P140K, has been described. 3 The vector was used to transiently transfect Phoenix-GALV packaging cells. The resulting virus-containing medium (VCM) was used to transduce 293T-based Phoenix-RD114 packaging cells, and an RD114-pseudotype, high-titer, packaging clone was identified. 
Flow-cytometric analysis
Flow-cytometric quantification of at least 20,000 events (gated by forward and right-angle light scatter and excluded for propidium iodide, 1 µg/mL) was performed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ). Analysis of flow-cytometric data was performed with CELLQuest v3.3 software (BD Biosciences, San Jose, CA) with gating to exclude fewer than 0.1% control cells in the relevant region for white blood cells. Control cells from a normal dog, matching the cell type assayed, were used to set the gates. FloJo software (Tree Star, San Carlos, CA) was used to score EGFP-expressing erythrocytes and platelets. The Overton subtraction algorithm was used to subtract background.
LAM-PCR
Integration site analysis by linear amplification-mediated PCR (LAM-PCR) was performed on canine DNA isolated from either total bone marrow (BM), peripheral blood leukocytes (PBL), or flow cytometric sorted cells. 100 ng of DNA served as template for LAM-PCR that was performed as described previously with modifications. 3, [30] [31] [32] Standard LAM-PCR 31, 32 was combined with a high-throughput screening method. 30 Briefly, Tas I and Msp I restriction genomic sequence, but due to the low homology between the canine and human genome, the placement of the sequence in the genome was not carried out.
Clone tracking
Three genomic primers were designed to sequences identified by LAM-PCR from populations sorted for expression of CD14 (i.e. monocytes) or a CD21-like antigen (i.e. B cells). To PCRamplify specific genomic insertion sites, a forward primer specific to the MSCV LTR (5'-TGCTTACCACAGATATCCTG -3'), and one of the three reverse genomic primers, two specific to sequences isolated from the CD14 subset population (1B : 5'-CCCTCCAGCGAGCCTAAGAT -3'), and (6C :5'-TGGACTGTGAGGCAAAGACG -3'), or one specific to a sequence isolated from the CD21 subset (21A: 5'-GAGTAGTAAAGCCATGCTGTGACTG -3') were used. Products were visualized on 1% agarose TAE gels. To ensure reproducibility of these results, we transplanted a second dog (G197) with autologous For For for dog G179 and 0.98 for dog G197. These data indicate that most gene-modified cells in both dogs carry a single proviral integration.
Results
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Multipotential repopulating cells are chemoprotected
The clonal composition of gene-modified hematopoiesis in dog G197 was analyzed by linear amplification mediated PCR (LAM-PCR). Initially, we performed LAM-PCR on DNA isolated from myeloid (granulocytes and monocytes) and lymphoid (T and B cell) subsets sorted to purity of 97.5-99.7% (322 days after transplantation, after 5 rounds of drug selection). The product of LAM-PCR was analyzed by gel-electrophoresis, and several bands were excised and sequenced.
In the gel-electrophoresis, after using generic LAM-primers, no common sequences were identified among the different subsets. To increase sensitivity, we designed three sets of primers specific to the genomic sequence flanking three individual insertion sites (two from CD14- 
Clonal composition at different time points before and after selection
We also analyzed the clonal composition of the gene-modified hematopoietic cells by LAM-PCR on different time points. DNA isolated from peripheral blood before selection ('pre'), after 4 cycles (G179) or 5 cycles (G197) of selection ('early'), and after 8 cycles (G179) and 9 cycles (G197) of selection ('late') was used as starting material for LAM-PCR, and the samples were separated by gel-electrophoresis (Figure 4 ). Both animals show contribution of multiple clones on all time points analyzed. In both animals we observed a tendency towards a reduction in clone number as assayed by gel electrophoresis. The total number of unique bands from three triplicate experiments for dog G179 was 32 before selection ('pre'), 11 after the early rounds of selection ('early'), and 7 after the last round of selection ('late'). The total number of unique bands from three triplicate experiments for dog G197 was 37 before selection ('pre'), 35 after the early rounds of selection ('early'), and 17 and 11 on 2 time points after the last round of selection ('late 1') and ('late 2').
To generate more sequence information, LAM-PCR product obtained from dog G197 on different time points after transplantation was shotgun-cloned without prior gel separation, 30 and a total of 25 unique sequences was identified. We found fifteen sequences before the first round of selection, ten of which were unique. Twelve sequences were identified after the fifth round of selection, all of them unique. Three sequences were identified after the last (ninth) round of drug selection, all three being unique. Interestingly, we found no overlap between 'pre', 'early' and 'late' sequences as assayed by random sampling of peripheral blood. This allows two interpretations: either there are different clones contributing to hematopoiesis before and after The linear amplification mediated PCR (LAM-PCR) has proven particularly useful to this end both in primary samples of animals undergoing gene therapy and in clinical trials. 3, 31, 32, 34 We have used this technology to gain a better understanding of the selection process occurring in the dogs presented in this study. We provide evidence that a long-lived cell with both lymphoid and We believe that our data should be rapidly translatable to clinical trials. Safety concerns regarding gene therapy have arisen after two cases of leukemia were described in patients treated by gene therapy for X-linked SCID. 34 Many experts consider the possibility that the occurrence of these severe adverse events was at least in part linked to the specific transgene used in this study. 35, 36 In support of this theory, leukemias have not been observed in clinical trials of stem cell gene therapy for diseases other than X-linked SCID. A recent retrospective study of a large series of canine and non-human primate recipients of gene modified hematopoietic stem cells also revealed no evidence of monoclonality or leukemia.
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However, for a number of malignant diseases, available treatment options are very limited. We believe that the potential benefits of drug resistance gene therapy outweigh the risks in the case of some highly refractory malignancies, especially in the case of glioma.
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Thus, clinical trials of gene therapy for these diseases seem warranted. 
